Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioDlink International CoHKSE:01875 62 Gross Margin % is 13.90% as of Dec. 2025, which is 81% below its 10-year median of 73.53. GuruFocus rates HKSE:01875 with a GF Score™ of 62/100 and a GF Value™ of HK$1.47 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 735 Biotechnology companies, BioDlink International Co ranks worse than 59.32% on this metric.
BioDlink International Co (HKSE:01875) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BioDlink International Co had a gross margin of 13.90% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BioDlink International Co Gross Margin % Related Terms
BioDlink International Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01875 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, BioDlink International Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioDlink International Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioDlink International Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BioDlink International Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BioDlink International Co (HKSE:01875) has a Gross Margin % of 13.90% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on BioDlink International Co and its competitors. This is 81% below median its historical median of 73.53. Over the past decade, BioDlink International Co's Gross Margin % has ranged from 36.00 to 91.78. According to the industry distribution chart, BioDlink International Co ranks #436 out of 735 companies in the Biotechnology industry, placing it in the top 59.3%.
Is BioDlink International Co's Gross Margin % too high?
BioDlink International Co's current Gross Margin % of 13.90% is 81% below median its 10-year median of 73.53. Over the past 10 years, this metric has ranged from a low of 36.00 to a high of 91.78. The Biotechnology industry median Gross Margin % is 60.91. BioDlink International Co's value of 13.90% is 77.2% below this industry median. Based on the distribution chart, BioDlink International Co ranks #436 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioDlink International Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioDlink International Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioDlink International Co ranks #436 out of 735 companies for Gross Margin %. This places BioDlink International Co in the lower half of its industry. The industry median Gross Margin % is 60.91. BioDlink International Co's value of 13.90% is 77.2% below this benchmark. Historically, BioDlink International Co's own Gross Margin % has ranged from 36.00 to 91.78 over the past decade. While the company's 10-year median is 73.53 vs. the industry median of 60.91, BioDlink International Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioDlink International Co's current Gross Margin % of 13.90% is 77.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on BioDlink International Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioDlink International Co's current Gross Margin % is 13.90%, which is 81% below median its own 10-year median of 73.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioDlink International Co stock overvalued right now?
Based on GuruFocus' analysis, BioDlink International Co (HKSE:01875) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.47, compared to a current price of HK$4.02 — trading 173.5% above its estimated fair value. The current Gross Margin % is 13.90%, which is 81% below median its 10-year median of 73.53 and 77.2% below the Biotechnology industry median of 60.91. BioDlink International Co's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For BioDlink International Co (HKSE:01875), the current Gross Margin % is 13.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioDlink International Co (HKSE:01875) Overvalued in 2026?
Based on GuruFocus' analysis, BioDlink International Co stock appears to be overvalued.
The current stock price of HK$4.02 is trading 173.5% above its estimated GF Value™ of HK$1.47.
GuruFocus considers BioDlink International Co to be Significantly Overvalued.
Key valuation signals for HKSE:01875:
Gross Margin %: 13.90% (81% below median its 10-year median of 73.53)
GF Value™: HK$1.47 vs. price of HK$4.02 (173.5% above fair value)
Industry Position: 77.2% below the Biotechnology median (#436 of 735)
No single metric tells the full story. See the HKSE:01875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and development (R&D), manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) business and license-out of self-developed biological drugs. The company has presence in Mainland China, and Others. The company's services includes ADC R&D Service Platform, Chemical based conjugation process development, Developability assessment for drug product, Drug substance analysis, Antibody Manufacturing, Drug product analysis, etc.
62GF Score
Get the complete analysis for HKSE:01875
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01875 has been successfully added to your 
